

Keenan[®]

Keenan Pharmacy Services
San Joaquin Valley Insurance Authority
(SJVIA)
Consultants Report: Q4 2025

SJVIA- EmpiRx Health – Q4 2025 Highlights

- SJVIA’s total plan cost increased by 6% in Q4 2025

	Q3 2025	Q3 2025	QoQ Change
SJVIA	\$10,184,947	\$10,845,833	6%
Tulare	\$4,272,075	\$4,364,072	2%
Fresno	\$5,912,872	\$6,481,761	10%

- Overall Script Count increased with a few channels seeing decreases. This could be attributed to additional fills due to the transition.

Category	SJVIA Q3 2025	SJVIA Q4 2025	QoQ Change	Tulare Q3 2025	Tulare Q4 2025	QoQ Change	Fresno Q3 2025	Fresno Q4 2025	QoQ Change
Retail Brand	5,431	6,096	665	2,315	2,415	100	3,116	3,681	565
Retail Generic	16,277	16,491	214	6,593	6,493	(100)	9,684	9,998	314
Retail 90 Brand	1,048	1,061	13	357	383	26	691	678	(13)
Retail 90 Generic	8,815	9,029	214	3,346	3,505	159	5,469	5,524	55
Mail Brand	139	128	(11)	63	52	(11)	76	76	0
Mail Generic	384	355	(29)	181	162	(19)	203	193	(10)
Specilaty	826	855	29	273	281	8	553	574	21
TOTAL	32,920	34,015	1,095	13,128	13,291	163	19,792	20,724	932

- Specialty claims plan cost decreased in Q4 2025

Category	SJVIA Q3 2025	SJVIA Q4 2025	QoQ Change	Tulare Q3 2025	Tulare Q4 2025	QoQ Change	Fresno Q3 2025	Fresno Q4 2025	QoQ Change
Retail Brand	\$4,533,356	\$4,783,101	\$249,745	\$2,052,269	\$2,069,938	\$17,669	\$2,481,087	\$2,713,163	\$232,076
Retail Generic	\$541,785	\$596,139	\$54,354	\$211,835	\$234,189	\$22,354	\$329,950	\$361,950	\$32,000
Retail 90 Brand	\$1,345,398	\$1,307,833	(\$37,565)	\$445,085	\$443,660	(\$1,425)	\$900,313	\$864,172	(\$36,140)
Retail 90 Generic	\$508,563	\$583,819	\$75,257	\$202,082	\$228,889	\$26,807	\$306,481	\$354,931	\$48,450
Mail Brand	\$236,283	\$229,987	(\$6,296)	\$103,865	\$91,941	(\$11,923)	\$132,419	\$138,046	\$5,627
Mail Generic	\$36,513	\$35,393	(\$1,120)	\$18,864	\$15,121	(\$3,743)	\$17,650	\$20,273	\$2,623
Specilaty	\$2,983,049	\$3,309,561	\$326,512	\$1,238,076	\$1,280,333	\$42,258	\$1,744,973	\$2,029,228	\$284,254



SJVIA- EmpiRx Health – Q3 2025 Highlights

- Enrollment Changes

	Sep-25	Dec-25	QoQ Change
SJVIA	13,578	12,462	(1,116)
Tulare	4,783	4,479	(304)
Fresno	8,795	7,983	(812)

- Patient Saver Plus Program Savings *(formerly known as Variable Copay Assistance (VCAP) aka bWell)*


	May 2025 - Sept 2025
SJVIA	\$562,621
Tulare	\$203,629
Fresno	\$358,992

- Rebates

Q1 - 2025	\$1,755,770
Q2 - 2025	\$2,175,410
Q3 - 2025	\$1,825,495
Q4 - 2025	Due by April 10, 2026

- Estimated Clinical Savings: Annual Guarantee is \$1,800,000


Q1 - 2025	\$1,051,335
Q2 - 2025	\$2,070,405
Q3 - 2025	\$1,955,923
Q4 - 2025	Due by April 10, 2026



Top Clinical Cost Drivers by Drug Q1 – Q4 2025

Top Drugs by Ingredient Cost
Based on Paid Date: 01/01/2025 - 12/31/2025

Drug Label Name	Drug Group	Claim Count 2025	Claim Count Q4	Utilizers 2025	Utilizers Q4	Ing Cost 2025	Ing Cost - Q4
WEGOVY	ANTI-OBESITY, ANOREXIANTS	2,936	766	460	40	\$4,170,408	\$1,094,585
ZEPBOUND	ANTI-OBESITY, ANOREXIANTS	3,543	1,326	613	119	\$4,169,722	\$1,572,997
OZEMPIC	ANTIDIABETICS	2,498	511	632	46	\$3,220,798	\$679,503
MOUNJARO	ANTIDIABETICS	2,401	704	352	30	\$3,128,610	\$908,974
DUPIXENT	DERMATOLOGICALS	346	86	42	4	\$1,478,676	\$381,128
JARDIANCE	ANTIDIABETICS	596	162	183	15	\$867,316	\$236,267
TREMFYA	DERMATOLOGICALS	50	13	17	1	\$741,473	\$194,221
RINVOQ	ANALGESICS - ANTI-INFLAMMATORY	79	20	11	0	\$568,015	\$138,252
SKYRIZI PEN	DERMATOLOGICALS	24	6	10	1	\$547,948	\$137,398
HUMIRA	ANALGESICS - ANTI-INFLAMMATORY	70	12	11	0	\$543,703	\$99,236
JYNARQUE	ENDOCRINE - METABOLIC	22	5	2	0	\$491,817	\$110,012
EMPAVELI	HEMATOLOGICAL AGENTS	11	1	1	0	\$444,544	\$39,650
BIKTARVY	ANTIVIRALS	97	22	13	1	\$416,135	\$95,097
ELIQUIS	ANTICOAGULANTS	351	80	91	5	\$410,497	\$98,797
STELARA	DERMATOLOGICALS	14	3	4	0	\$386,548	\$89,739
FARXIGA	ANTIDIABETICS	239	67	89	11	\$358,523	\$97,604
TRULICITY	ANTIDIABETICS	220	59	44	0	\$316,450	\$78,884
RYBELSUS	ANTIDIABETICS	184	37	45	4	\$306,267	\$62,992
KESIMPTA	PSYCHOTHERAPEUTIC - NEUROLOGICAL	30	17	3	1	\$305,088	\$181,146
NURTEC	MIGRAINE PRODUCTS	180	50	44	5	\$304,780	\$87,540
TRELEGY ELLIPTA	ANTIASTHMATIC - BRONCHODILATOR	336	183	93	31	\$283,474	\$149,995
TASIGNA	ANTINEOPLASTICS - ADJUNCTIVE	17	0	2	2	\$267,790	\$267,790



Pharmacy Market Updates

- **Oral GLP-1 Medications**

- The first oral GLP-1 medication specifically for weight loss, the **Wegovy pill (semaglutide)**, became available in the U.S. in early January 2026. It offers a daily, needle-free alternative to injections for chronic weight management.
- Requires Prior Authorization under CarleonEx as do all GLP-1 Medications

